The seventh annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum will be held in West Palm Beach, Florida, from Feb. 24–26. With this year’s theme of Biomarkers in MS, the event will highlight leading scientific discoveries that aid in our understanding of MS and the care of MS patients.
Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL…
Read moreElectrically stimulating the brain while doing at-home cognitive training games can help to prevent a decline in cognition for people with multiple sclerosis (MS), particularly those with more advanced disability, a study indicates.
Tolebrutinib, an investigative inhibitor of Bruton’s tyrosine kinase (BTK) being developed by Sanofi to treat all forms of multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in…
Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model…
Hormonal changes over time — and especially those around menopause — are often associated with disability worsening in multiple sclerosis (MS) patients, which suggests that sex-specific hormone therapies may be useful in MS…
The experimental medication ublituximab significantly reduces the number of new brain lesions with severe nerve cell degeneration in people with relapsing multiple sclerosis (MS) as compared with Aubagio (teriflunomide), according to new…
A higher burden of lesions in the brain’s cortex is associated with a greater likelihood of disability worsening in multiple sclerosis (MS) and transition to secondary progressive MS (SPMS), researchers report. These…
A faster rate of atrophy in the spinal cord of people in earlier stages of multiple sclerosis (MS) is likely to indicate “silent progression” — worsening disability in the absence of relapses — and…
People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio…
Iron rim lesions, or specific regions of chronic inflammation seen on MRI scans of the brain, are associated with greater disability and poorer outcomes in multiple sclerosis (MS), a study indicates. These findings…
Get regular updates to your inbox.